Novel effect of glucagon-like peptide-2 for hepatocellular injury in a parenterally fed rat model of short bowel syndrome

Preclinical study demonstrates that low-dose GLP-2 (1 µg/kg/h) significantly reduces hepatic steatosis and inflammation in a rat model of short bowel syndrome receiving total parenteral nutrition. Findings suggest GLP-2 may have therapeutic potential beyond bowel adaptation for preventing intestinal failure-associated liver disease in SBS patients.